Trial
NCT03351231
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Cancer
Intervention
BMS-986242
Why stopped
Inability to meet protocol objectives
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-26